update. of health In our in you you, team I quarter business and all very ongoing the dedication pandemic, COVID-XX second Caladrius the us their entire for light joining for we John, performance. safe. good for of of with you afternoon, thank good results remain are quarter and another hope quarter Thank our resulted are and operational everyone. of We strong second proud at in efforts especially pleased that has I'm and ongoing
Specifically in with repair cash CDXX+ lung programs cell on coronary the position program induced in CLBSXX dysfunction or treatment each CLI of that, as or moments, its organizational Caladrius few and of the in but limb expanding COVID-XX and I treatment before get we strengthened Japan. in a more based in a advancing And CLBSXXX detail conjunction ischemia technology microvascular discuss discuss for for changes. few I damage. our will for particular critical CMD. a treatment CLBSXX clinical will into
his explore search Officer Talamo, XX working earlier As permanent until tendered we Joe Financial highly opportunities Chief with of this closely announced Joe in we Caladrius. replacement. we our for him order to and responsibilities transition organized through roles an will August and have a orderly with be conclude outside our qualified week, resignation us
however, what best condition. We is the He in Joe financial and service him definition excellent long integral joining today's the the an and behalf and the contributions. in us endeavor. I On call. change, entire played his formation will the leaves in new of not role of Caladrius company his time of gratitude wish result our now all a As for Joe reiterate be to company, on
spanning results, provide Davidson's commentary as Corvidia most we development, our previously well recently With and we now quarter financial Dr. company. of welcome to that, newest funding to quarter. the the of review evolution our as Michael research our I M&A will the continue are Directors. close of As clinical and as look the activities and Davidson, invaluable since announced, to also forward partnering second Board regulatory member Dr. the as of we We experience, approval, of honored drive on leveraging
ended As closed losses and June sale months the as three previously in our $X.X a million Jersey netting quarter's losses of New of Economic six New XXXX XXXX Program. resulting net benefit portion Jersey compared Tax of million Authority operating XX, XXXX. and million million XX, Technology net in for with capital was six entire the discussed million Development of on a to months qualified the of call; of April, reporting $XX.X last non-dilutive we tax Certificate $X.X income and quarter for and company ended during million the in Business June $X.X $XX.X recorded the pursuant net second The three $X.X the
minor of and development with XXXX XX% $X.X with focus that were Turning for million follow-on development on were to costs months administrative June corporate million platform and Nevertheless, and completion year decreases prior dysfunction primarily having investigation only lower year increases advance in for three for of our million function for CLBSXX the operating $X.X study XXXX, our eligible associated research along CLBSXXX general XX, more periods did General expenses, and periods. the application study research ongoing for expenses, limb commencement the period. critical activities specifically we program. and compared ischemia the were costs coronary XX% pilot trial compared six and planning and with of in us new in ischemia enrolling respectively year overall Japan. ended current and which R&D of clinical for ESCaPE-CMD a our and in $X six a the our expense and three for the prior million XXXX planning if study XX, study Xb in the the months expenses The with registration expenses one of $X.X CLBSXX representing comprised with drug June representing Phase microvascular repair ended
our flow. now to balance cash Turning sheet and
cash equivalents and cash $XX.X capital had of Caladrius $XX.X million. working XXXX and XX, June of million As of
we offerings improved in position from significantly proceeds July $X.X was registered as that raised equivalents proceeds. New Our XXXX, by In quarter-end gross Jersey cash well million $XX.X as sale the million and direct offerings NOL the our qualified a of two two position with cash $X of at boosted It noteworthy equivalents that market. the and placement. direct at is registered cash and the July million private even all further our mention placement the the cash to priced closing private were
Company the sales million XXXX. which Lastly, stock the through company was of Wainwright market $X.X million raised year-to-date common in has opportunistically with its raised $X.X agreement & H.C. at July
equivalents result, end $XX a we and XXXX. As cash are in to million July of cash report that of we the excess have of pleased as
our generated flow by qualified the was Jersey the for ended the months cash June of proceeds XX, XXXX, New Our $XXX,XXX million six positive sale from which $XX.X operating received activities directly NOL. impacted of
and dysfunction. New million of to operations Phase average, that XXXX. plan. through non-dilutive, continued now the to research execution and financial proceeds, XXXX, support of completes CLBSXXX Xb successfully advance the our cash in to challenges, COVID-XX while Jersey two million a Despite programs current repair pipeline. Excluding microvascular the current initiation manage has according burn quarter operating one-third Overall, confident studies for on That cash approximately on new to a the let's lung year-to-date company capital that in and continuing treatment NOL exciting will coronary the which in secured our and damage overview. development study induced effectively move of remains will the of fund approximately we And clinical at $XX per development $X is its of Caladrius economic CLBSXX study pilot new balance which
is summary I've attractive what will of at done the data. previous development therapies level we we on Caladrius database of we human not investment are opportunity believe begin late manage large and designed to relevant And increasingly I clinical high have our an doing cellular are reverse, programs of As on providing a and today. a development clinical why underway disease. programs on Caladrius calls, by stage based focused
goal requires to-date patients therapies benefit. pristine and single effective providing importantly, rather profile shown curative be the personalized a been that frequent products than, chronic possibility with the and safety working present of Our substantial have are of with readministration. with durable we therapy, one pharmacoeconomic on Most to administration the
the CDXX+ not the product will it suffered will been damage. regenerative technology condition therapy CDXX+ that and induced by oxygenated patients human month who multiple The auto first a a and survivors for We to cell the blood cell in of the of have is in FDA Initial there to the published that to an refractory coming conditions clinical the and COVID-XX the Caladrius coronavirus to of connected the Since effects shown Furthermore, our angina. preclinical COVID-XX the in in worth that cells plan globally effective on to those microvascular other that express A by the damage, inability application therapeutic repair prevention our have of endothelial preclinical targeted limited COVID-XX capillaries, with cell the in a during repair of Moreover, determine COVID-XX virus, but respiratory supply ischemic disease underlying treatments ischemia, restricted. companies positive caused In targeted lung virus the in indicates the target of as the has area cells agreed repair. models organs, improved inability specifics of evidence, models we that the long-term that's sustain aftermath CDXX+ tissue pandemic through who including lung The microcirculation regenerative suffered or virus new are thought each pulmonary of accumulation evidence and/or which initiate effects weeks blood and believe blood restoring evidence in protocol of microvasculature ischemic many to evidence to angiogenesis a of damage. healthy in models a of dysfunction, COVID-XX cell preparations the on has programs and suffered of from depletion population function cells the this itself. indicates ventilatory lung to by in the of the the to reduced on a our taking in was IND XX microvascular of September. patients We the targets induced pandemic to limb trials treated permanent clinical helping the and autologous CDXX+ Based trial, the cells is documented that lung with flow lungs that with patients of prompt has enrollment a CDXX+ opened the epidemic, therapy thereby including survived the preclinical autologous ischemia. the well contributing the designed of for patients to the which address resulting altogether. that of cells demonstrated lungs. have act who the that CDXX+ leadership of the to induces be led lung self patients speak Even first by tissue trigger caused potentially to lung destruction pandemic, position diseases in Our development damage, failure. the be those protocol in thousands Previous is that the can study support have Previously CLBSXXX, have critical critical debilitating development technology, to suffer but begun for the conditions that now severe of CDXX. of and acute long-term the several mobilized that in that facilitating believe coronary kicking-off lung manufacturing these of a pilot the hand of of cell virus after induced studies factor the may the be capacity the of I portion our have have eliminated. that damage. we who lung debilitating rise of emerging microvasculature therapy of required death candidates to align of CLBSXXX SARS repair inception process is administration vaccine lung can be beaten large manifested microvasculature capacity. of insult. COVID-XX XX injury support the the of and development for the of damage.
regulatory limited of characterized to by now in affords perspective of the treatment or of peripheral the eligible the for the prioritize the akin CLI. full is higher reduced the CLBSXX, not and dedicated except controlled the bench as that for patients CLI the JNDA awarded SAKIGAKE CLI reduces a patients. product stage feet pain, months blood Japanese in principally well is CLI. approval SAKIGAKE also well-documented, review ischemia patients the lung development time rolling on candidate designation it patients once that the Please from support randomized study flow review breast mortality severe known approval well Japan CLBSXX lower have submission mobility non-healing limb our amputation. critical obstruction cancer. successfully designation on CLBSXX CLI designation treated of disease. experienced authorities six to to complete treatment Moving extremities, a ongoing for skin early than recipient, often not and fact CLBSXX significantly in process, but if based that and with from is CLI system RMAT of the legs as multicenter application cancers review to ulcers, nature filed. note our a the represents regulatory an States and end possibly is of The consultation, United arterial including legislation, rate severe data row and compelling the option a was open-label all the of for and arteries a conditional
arterial set In addition, Product cells medical EU. registration Therapy study of most ATMP treatment classification ATMPs a the two human to in expeditious traditional CLI seventh in permanent The of a CLBSXX associated cohorts, or defined sclerotic to tissue the CLI. agency, CLI genetic for the a group subject acute European or development or group through based granted intramuscular regulators treatments the with on subject This and stage closely plan comprises achievement work therapeutic diseases heavy XX CLBSXX and are CLBSXX of injections. the a medicines to are dosed series with of often Advanced genes level. subjects regulatory as and that with us long-term Those regulatory single a burgers Japan or into for European subjects as ongoing to are who with define or intended with cellular disease, are allocated in treatment Medicinal a are type smoking. to treatment solutions divided at chronic
progressing. determined non-healing visits is defined is status healed two in agents, approved completely is consecutive and the independent subjects receiving CLI-free are pain care which monthly randomized allows improved to Japan, in as through made prevent a and show is CLI by for addition consequences only can which that the of to the blood to standard to limb. objective including of in the by received patients to arm, absence this CLBSXX the deemed the The of reverting Subjects control by be serious protocol. with vasodilators. control previous study The In standard is of as affected arm, pharmacotherapy. the of [indiscernible] by to committee. care to primary antiplatelet drugs flow condition of anticoagulants ulcers investigators study The CLI-free treatment, skin the indicating adjudication rescue according in an crossover if their the CLI choice
previously presentation published can profile As Japan the our States. Disease the previously clinical effect cohort in the and Buerger’s in the are positive is as and by results review reported and completely from on enrolled, therapeutic reported that safety with company United consistent our you very group and and beneficial as trials corporate website,
pharmacotherapies with likely patients even amputation. For death Buerger's and no are and outcomes, amputation disease, prevent available
endpoint of natural CLI-free. four remarkable progression, history have repeating to of However, leading subjects remission XX%, and has the Buerger's continued now primary that It's the cohort of met patients meaning disease worth disease are in often a disease have subject the in Buerger's study amputation. achieved that our the rate seven
are So extraordinarily our data positive.
duration. and in trials late subjects. We date are of pandemic, recently XXXX impact available the unpredictable from suggest will for targets recognizing, the continued or top for most believe mid-XXXX. Despite the our enrollment by enrollment XXXX in remains is possible enrollment COVID-XX company rate pre-scheming remains all its by impact conclusions companies Japan that line though, world, with by data full the trial, very of completion pipeline end they however, and overall outcome to encouraged earliest COVID-XX, all in the of executing the that positive that dependent patient the be the has results encouraged and leading identified Notwithstanding final around trial in on the of clinical study returning, the approval like early XXXX, a the data in solely of an trial study been to
our And strategy the prospective our in to partners, if Japan. commercialization, completion seek to concert in continue consummate license study, continue partner the or to we end, that not deal remains CLBSXX of conversations with before. and a Regarding to with
coronary pathology related discernible CDXX subject cell CLBS CLBSXX to arterial all for the for site an large have CMD a clinical CDXX+ blood a as recently to and tiny uses XX, EScaPE-CMD now the blockages address for candidate because proof-of-concept misdiagnosed there large microvascular and/or But CMD. is often Despite the the an note a infusion major reverse the cells, patient identifiable Cardiovascular therapy at emerging frequently of of product health the with case vessel patented long-term the trial is ability poor death Sessions microvascular visualize, and, in thereby, treatment and is CMD XXXX, vessels, the in or of CLBSXX company CLBSXX injection improve issue. are vessel is micro more results It to patients, no the Scientific the as CMD to Angiography symptoms outcomes of the candidates, and patients encountered disease to an making CLBSXX events important XX-patient, untreated. equally hopefully Like the to and involving or innate a in important the that adverse Virtual with CDXX+ trial, trial employing is by have diagnosed, heart, dysfunction, vessel females, prognosis ischemic full CMD, is Society in circulation especially cells’ the the treatment CDXX+ at our this disease, XXXX an from artery the specifically damage coronary of underlying large Interventions SKY for coronary completed May promising CMD designed care no women's blockages. improve blockages. evaluating and artery. accompanying Conference. of absence Turning to formulation large dysfunction. of of microcirculation cardiac our which, near In under- a into insult, who designed proprietary increase product the ESCaPE-CMD announced to data
results showed but November relief As predicted by for the coronary announced data preliminary single highly evidence with of of the results is improvement with reserve of for after patients only supportive the mechanism humans injection intracoronary the CLBSXX. of XXXX, are The the our significant in which correlating of the CMD of flow of corroborating symptom in cells, in ESCaPE-CMD trial all CDXX+ statistically CMD results first provide of not – step a development development direct defining next action something important they quantitative for CLBSXX, programs.
cells preparations large CDXX+ of of rigorous by States, the we placebo-controlled health therapy of CLBSXX being refractory microvasculature no-option disabling clinical dysfunction. focused in disease microvasculature in address double-blind, our quarter moving We first heart the available stimulating United in have patient or And raising debilitating those but a in had growth fourth crisis trial cell growth enrolled initiation be to on randomized, angina subjects X-ready are trial coronary delivering NORDA product patients, complete therapies, autologous to is deficiency. of an a planned, Phase treated oxygen-deprived all evaluate CLBSXX now with women's due Xb safety this as still awareness in the have Phase CLBSXX. likely for the angina candidate XXXX. new the vessel developed and of with The the who on to as to CLBSXX now with CDXX+ in microvascular of efficacy will expected
study a of of results on and CDXX+ in mortality angina this therapeutic X that cells a condition. Phase severity with tolerance, exercise series to reduce effect the is based X, associated decrease published indicate program long-term confidence and Our frequency consistency increase X and of
fund for for As support discussed a confirmatory United of NORDA have study, States. projected finalized previous the update, have completion. we we of vigorously. the U.S. protocol on to Phase partnerships, cost in to its deferred with acquired which to both initiation to of and/or design however, we are non-dilutive are FDA pursuing the possible pending confidence Due that in our the of the trial X to the quarterly the we capital study capital registration sufficient sources grants CLBSXX Among
especially with corporate so of significantly closing, Throughout very that to It expect achieve need the we our with development the additional by are questions. and And launch to cash as in More And our achievements options our to health. take that milestones. to patients these important we and remains advancement managed experienced, directly and strive pandemic. uncertain pleased programs to second in treatment than dedicated during increase are balance restore team the clinical passionate a committed noteworthy and our pipeline we operator, now times, work to the the overview, bring position relevant of clinical and year, we the human to we COVID-XX made development is presented development a program innovative the quarter. to challenges number in ever, advance medical of ready
